Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance

coban, neslihan; KAYA, AYŞEM; ADEMOĞLU, Evin; Erkan, Aycan Fahri; kurmus, ozge

doi:10.14744/ijmb.2021.91886

Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance

Özge KURUMUŞ, (Ufuk Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Aycan FAHRİ ERKAN, (Ufuk Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Neslihan ÇOBAN, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Genetik Anabilim Dalı, İstanbul, Türkiye)

Ayşem KAYA, (İstanbul Üniversitesi-Cerrahpaşa, Kardiyoloji Enstitüsü, Biyokimya Laboratuvarı Anabilim Dalı, İstanbul, Türkiye)

Evin ADEMOĞLU (İstanbul Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, İstanbul, Türkiye)

International Journal of Medical Biochemistry

4 2

Yıl: 2021 Cilt: 4 Sayı: 2 Sayfa Aralığı: 85 - 90 Metin Dili: İngilizce DOI: 10.14744/ijmb.2021.91886 İndeks Tarihi: 03-02-2022

Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance

Öz:

Objectives: The aim of this study was to investigate whether serum apolipoprotein E (ApoE) and adiponectin were as sociated with discordance of low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol(non-HDL-C) levels in coronary artery disease (CAD) patients. Methods: A total of 243 patients with significant CAD were studied. The fasting levels of serum lipids, plasma ApoE,and adiponectin were measured. The median LDL-C and non-HDL-C values were determined to assess and analyzediscordance. Discordance was defined as an LDL-C≥ the median and non-HDL-C< the median, or an LDL-C< the medianand a non-HDL-C≥ the median. ApoE and adiponectin were compared between discordant and concordant groups. Results: Discordance between the LDL-C and the non-HDL-C was observed in 14% of the patients. Although the me dian adiponectin was lowest in the group with an LDL-C< median and a non-HDL-C≥ the median, and the median ApoEwas lowest in the group with an LDL-C≥ median and a non-HDL-C< the median, no statistically significant differencesin the ApoE and adiponectin were recorded between the groups (p=0.186 and p=0.161, respectively). Adiponectin wasnegatively correlated with triglyceride and remnant cholesterol (p<0.001 and p<0.001, respectively). Conclusion: While discordance between the LDL-C and the non-HDL-C in CAD patients (14%) was observed, the plas ma ApoE and adiponectin levels were not significantly different between the discordant and concordant groups.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, et al; TNT Study Group; IDEAL Study Group. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008;117(23):3002– 9.
2. Marais AD. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. Pathology 2019;51(2):165–76.
3. Gibson JC, Rubinstein A, Bukberg PR, Brown WV. Apolipoprotein E-enriched lipoprotein subclasses in normolipidemic subjects. J Lipid Res 1983;24:886–98.
4. Cohn JS, Tremblay M, Amiot M, Bouthillier D, Roy M, Genest J Jr, et al. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol 1996;16(1):149–59.
5. Yu H, Zhang W, Yancey PG, Koury MJ, Zhang Y, Fazio S, et al. Macrophage apolipoprotein E reduces atherosclerosis and prevents premature death in apolipoprotein E and scavenger receptor-class BI double-knockout mice. Arterioscler Thromb Vasc Biol 2006;26(1):150–6.
6. Söderlund S, Watanabe H, Ehnholm C, Jauhiainen M, Taskinen MR. Increased apolipoprotein E level and reduced high-density lipoprotein mean particle size associate with low highdensity lipoprotein cholesterol and features of metabolic syndrome. Metabolism 2010;59(10):1502–9.
7. Barbagallo CM, Rizzo M, Noto D, Frasheri A, Pernice V, Rubino A, et al. Accumulation of apoE-enriched triglyceriderich lipoproteins in patients with coronary artery disease. Metabolism 2006;55:662–8.
8. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103(8):1057–63.
9. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100(25):2473–6.
10. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257(1):79–83.
11. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adiposespecific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20(6):1595–9.
12. Oliveira GB, França JÍ, Piegas LS. Serum adiponectin and cardiometabolic risk in patients with acute coronary syndromes. Arq Bras Cardiol 2013;101(5):399–409.
13. Elshazly MB, Martin SS, Blaha MJ, Joshi PH, Toth PP, McEvoy JW, et al. Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study (very large database of lipids). J Am Coll Cardiol 2013;62(21):1960–5.
14. Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation 2014;129(5):553–61.
15. Kurmus O, Erkan AF, Ekici B, Aslan T, Eren M. Discordance of low-density lipoprotein cholestrol and non-high-density lipoprotein cholestrol and coronary artery disease severity. Arq Bras Cardiol 2020;114(3):469–75.
16. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983;51(3):606.
17. Chruściel P, Sahebkar A, Rembek-Wieliczko M, Serban MC, Ursoniu S, Mikhailidis DP, et al; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis 2016;253:194–208.
18. Alaupovic P, Hodis HN, Knight-Gibson C, Mack WJ, LaBree L, Cashin-Hemphill L, et al. Effects of lovastatin on ApoA- and ApoB-containing lipoproteins. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS). Arterioscler Thromb 1994;14:1906– 13.
19. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50(9):2094–9.
20. Modi KD, Chandwani R, Ahmed I, Kumar KV. Discordance between lipid markers used for predicting cardiovascular risk in patients with type 2 diabetes. Diabetes Metab Syndr 2016;10(1 Suppl 1):S99–S102.
21. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al; ESC Scientific Document Group. 2019 ESC/ EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41(1):111–88.
22. Wilson HM, Patel JC, Russell D, Skinner ER. Alterations in the concentration of an apolipoprotein E-containing subfraction of plasma high density lipoprotein in coronary heart disease. Clin Chim Acta 1993;220:175–87.
23. Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V, Murphy BD, Palin MF. Adiponectin action from head to toe. Endocrine 2010;37(1):11–32.
24. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291(14):1730–7.
25. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al; Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23(1):85–9.
26. Schnabel R, Messow CM, Lubos E, Espinola-Klein C, Rupprecht HJ, Bickel C, et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur Heart J 2008;29(5):649–57.
27. Hascoet S, Elbaz M, Bongard V, Bouisset F, Verdier C, Vindis C, et al. Adiponectin and long-term mortality in coronary artery disease participants and controls. Arterioscler Thromb Vasc Biol 2013;33(1):e19–29.
28. Wu ZJ, Cheng YJ, Gu WJ, Aung LH. Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: a systematic review and meta-analysis. Metabolism 2014;63(9):1157–66.
29. von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem 2006;52(5):853–9.
30. Izadi V, Farabad E, Azadbakht L. Epidemiologic evidence on serum adiponectin level and lipid profile. Int J Prev Med 2013;4(2):133–40.
31. Weiss R, Otvos JD, Flyvbjerg A, Miserez AR, Frystyk J, Sinnreich R, et al. Adiponectin and lipoprotein particle size. Diabetes Care 2009;32(7):1317–9.

APA	kurmus o, Erkan A, coban n, KAYA A, ADEMOĞLU E (2021). Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance. , 85 - 90. 10.14744/ijmb.2021.91886
Chicago	kurmus ozge,Erkan Aycan Fahri,coban neslihan,KAYA AYŞEM,ADEMOĞLU Evin Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance. (2021): 85 - 90. 10.14744/ijmb.2021.91886
MLA	kurmus ozge,Erkan Aycan Fahri,coban neslihan,KAYA AYŞEM,ADEMOĞLU Evin Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance. , 2021, ss.85 - 90. 10.14744/ijmb.2021.91886
AMA	kurmus o,Erkan A,coban n,KAYA A,ADEMOĞLU E Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance. . 2021; 85 - 90. 10.14744/ijmb.2021.91886
Vancouver	kurmus o,Erkan A,coban n,KAYA A,ADEMOĞLU E Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance. . 2021; 85 - 90. 10.14744/ijmb.2021.91886
IEEE	kurmus o,Erkan A,coban n,KAYA A,ADEMOĞLU E "Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance." , ss.85 - 90, 2021. 10.14744/ijmb.2021.91886
ISNAD	kurmus, ozge vd. "Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance". (2021), 85-90. https://doi.org/10.14744/ijmb.2021.91886

APA	kurmus o, Erkan A, coban n, KAYA A, ADEMOĞLU E (2021). Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance. International Journal of Medical Biochemistry, 4(2), 85 - 90. 10.14744/ijmb.2021.91886
Chicago	kurmus ozge,Erkan Aycan Fahri,coban neslihan,KAYA AYŞEM,ADEMOĞLU Evin Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance. International Journal of Medical Biochemistry 4, no.2 (2021): 85 - 90. 10.14744/ijmb.2021.91886
MLA	kurmus ozge,Erkan Aycan Fahri,coban neslihan,KAYA AYŞEM,ADEMOĞLU Evin Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance. International Journal of Medical Biochemistry, vol.4, no.2, 2021, ss.85 - 90. 10.14744/ijmb.2021.91886
AMA	kurmus o,Erkan A,coban n,KAYA A,ADEMOĞLU E Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance. International Journal of Medical Biochemistry. 2021; 4(2): 85 - 90. 10.14744/ijmb.2021.91886
Vancouver	kurmus o,Erkan A,coban n,KAYA A,ADEMOĞLU E Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance. International Journal of Medical Biochemistry. 2021; 4(2): 85 - 90. 10.14744/ijmb.2021.91886
IEEE	kurmus o,Erkan A,coban n,KAYA A,ADEMOĞLU E "Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance." International Journal of Medical Biochemistry, 4, ss.85 - 90, 2021. 10.14744/ijmb.2021.91886
ISNAD	kurmus, ozge vd. "Apolipoprotein E and adiponectin levels in coronary arterydisease patients with low-density lipoprotein cholesterol andnon-high-density lipoprotein cholesterol discordance". International Journal of Medical Biochemistry 4/2 (2021), 85-90. https://doi.org/10.14744/ijmb.2021.91886